They are a clinical stage biopharmaceutical company focused on applying their proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.
November 8, 2017
J.P. Morgan, Leerink Partners, BMO Capital Markets
To view the prospectus for Fireman B.V. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277